Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of “Buy” from Brokerages

Bioventus Inc. (NASDAQ:BVS) has been given an average recommendation of “Buy” by the six analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $16.25.

Several analysts recently weighed in on the company. Craig Hallum restated a “buy” rating and set a $18.00 price target on shares of Bioventus in a report on Thursday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of Bioventus in a research note on Tuesday, June 16th. Weiss Ratings upgraded shares of Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Finally, Barrington Research set a $18.00 target price on shares of Bioventus in a research note on Thursday.

Institutional Trading of Bioventus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Engine Capital Management LP purchased a new position in shares of Bioventus during the first quarter valued at approximately $2,876,000. Hillsdale Investment Management Inc. grew its stake in shares of Bioventus by 148.7% during the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after buying an additional 401,230 shares during the last quarter. Fifth Third Bancorp purchased a new stake in shares of Bioventus in the first quarter worth approximately $1,478,000. Wesbanco Bank Inc. purchased a new stake in shares of Bioventus in the first quarter worth approximately $895,000. Finally, Legato Capital Management LLC lifted its stake in shares of Bioventus by 1,042.8% during the 4th quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock worth $1,023,000 after acquiring an additional 125,525 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus Trading Up 1.1%

Shares of NASDAQ BVS opened at $14.13 on Friday. Bioventus has a 1-year low of $6.26 and a 1-year high of $15.89. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.69 and a quick ratio of 1.13. The business’s 50 day moving average is $10.81 and its two-hundred day moving average is $9.69. The stock has a market capitalization of $1.18 billion, a P/E ratio of 18.35, a PEG ratio of 1.80 and a beta of 0.63.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.22. The business had revenue of $153.21 million during the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, research analysts expect that Bioventus will post 0.79 EPS for the current year.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.